
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday released clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its oral STAT6 degrader medicine.
STAT6 degradation is a novel oral approach for blocking the IL-4/IL-13 pathways in development for the treatment of atopic dermatitis and other allergic diseases.